Neuren Pharmaceuticals Partner Projects $700M Global Sales for Rett Syndrome Drug by 2028 as Australian Shares Stay Flat

Neuren Pharmaceuticals Forecasts Major Growth in Rett Syndrome Drug

Neuren Pharmaceuticals Ltd, listed on the ASX as NEU, has projected global sales of up to US$700 million for its Rett syndrome treatment, trofinetide, by 2028. The announcement reflects confidence in the drug’s commercial potential following recent clinical and regulatory milestones in the United States and Europe. Investors are closely monitoring these projections, as the market anticipates the launch of a therapy that could transform treatment for patients with rare neurodevelopmental disorders.